Ocugen, Inc. (OCGN) |
|
2.1 0.19 (9.95%)
|
05-16 08:26 |
|
Open: |
1.95 |
Pre. Close: |
1.91 |
|
High:
|
2.13 |
Low:
|
1.89 |
|
Volume:
|
8,940,336 |
Market Cap:
|
453(M) |
|
|
|
|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.13 - 2.14 |
2.14 - 2.15 |
|
Low:
|
1.87 - 1.88 |
1.88 - 1.89 |
|
Close:
|
2.08 - 2.1 |
2.1 - 2.12 |
|
Technical analysis |
as of: 2022-05-16 7:50:27 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.93  One year: 3.55 |
| Support: |
Support1: 1.67 Support2: 1.38 |
| Resistance: |
Resistance1: 2.51 Resistance2: 3.03 |
| Pivot: |
2.18 |
| Moving Average: |
MA(5): 2.01  MA(20): 2.27
MA(100): 3.3 MA(250): 5.92 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 43.1 %D(3): 29 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 17.64 Low: 1.67 |
| Average Vol(K): |
3-Month: 11,248 (K) 10-Days: 7,959 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OCGN ] has closed above bottom band by 38.2%. Bollinger Bands are 48.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Mon, 09 May 2022
Ocugen stock slips 8% as Chardan Capital cuts PT (NASDAQ:OCGN) - Seeking Alpha
Sun, 08 May 2022
Ocugen (NASDAQ:OCGN) versus Codiak BioSciences (NASDAQ:CDAK) Head to Head Review - Defense World
Fri, 06 May 2022
Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript - The Motley Fool
Thu, 28 Apr 2022
The FDA Just Sent Ocugen a Warning. Should Investors Care? - The Motley Fool
Wed, 27 Apr 2022
Where Will Ocugen Stock Be In 5 Years? - Seeking Alpha
Thu, 21 Apr 2022
Ocugen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.9919e+008 (%) |
|
% Held by Institutions
|
1.9514e+008 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.1e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.26 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
12 |
|
Return on Assets (ttm)
|
148 |
|
Return on Equity (ttm)
|
346.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.16 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.27 |
|
Qtrly Earnings Growth
|
-4.597e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-8.31 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
5.43e+007 |
|
Forward Dividend
|
4.693e+007 |
|
Dividend Yield
|
2585710000% |
|
Dividend Pay Date
|
2019-09-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
